The combination of an mTORc1/TORc2 inhibitor with lapatinib is synergistic in bladder cancer in vitro.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Urologic oncology

• Publication date

  2014-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.urolonc.2013.06.002PMID 24054871PMCID PMC4559860
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models.

  2012cited by this paper
• Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy

  2012cited by this paper
• Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies.

  2012cited by this paper
• mTOR signaling in growth control and disease.

  2012cited by this paper
• Cancer statistics, 2012

  2012cited by this paper
• Deconvoluting the context-dependent role for autophagy in cancer

  2012cited by this paper
• Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis.

  2011cited by this paper
• Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin

  2011cited by this paper
• Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience

  2011cited by this paper
• Inhibition of mTOR Kinase by AZD8055 Can Antagonize Chemotherapy-induced Cell Death through Autophagy Induction and Down-regulation of p62/Sequestosome 1*

  2011cited by this paper
• The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers

  2011cited by this paper
• mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling.

  2011cited by this paper
• Hypoxia‐inducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: possible therapeutic implications

  2011cited by this paper
• Urothelial carcinomas: a focus on human epidermal receptors signaling.

  2011cited by this paper
• Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma.

  2010cited by this paper
• Drug combination studies and their synergy quantification using the Chou-Talalay method.

  2010cited by this paper
• The epidermal growth factor receptor antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1alpha and Bcl-2 and activating the beclin 1/hVps34 complex.

  2010cited by this paper
• Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

  2010cited by this paper
• FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy

  2010cited by this paper
• Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients

  2009cited by this paper
• Inactivation of p53 and Pten promotes invasive bladder cancer.

  2009cited by this paper
• Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2

  2009cited by this paper
• Intravesical Delivery of Rapamycin Suppresses Tumorigenesis in a Mouse Model of Progressive Bladder Cancer

  2009cited by this paper
• Rapamycin inhibits in vitro growth and release of angiogenetic factors in human bladder cancer.

  2009cited by this paper
• A single‐arm, multicenter, open‐label phase 2 study of lapatinib as the second‐line treatment of patients with locally advanced or metastatic transitional cell carcinoma

  2009cited by this paper
• Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer

  2009cited by this paper
• Heparin‐binding epidermal growth factor‐like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome

  2007cited by this paper
• FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma

  2005cited by this paper
• Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

  2003cited by this paper
• Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.

  2001cited by this paper
• Cancer statistics

  1989cited by this paper
• www.kjurology.org DOI:10.4111/kju.2011.52.7.466 Urological Oncology Role of the mTOR Pathway in the Progression and Recurrence of Bladder Cancer: An Immunohistochemical Tissue Microarray Study

  year unknowncited by this paper

• Targeting autophagy drug discovery: Targets, indications and development trends.

  2024cites this paper
• Landscape of targeted therapies for advanced urothelial carcinoma

  2024cites this paper
• The mTOR Signaling Pathway and mTOR Inhibitors in Cancer: Next-generation Inhibitors and Approaches.

  2023cites this paper
• Bladder Cancer Prevention: Potential Molecular Targets and Their Clinically Relevant Agents

  2023cites this paper
• Anti-tumor effect of AZD8055 against bladder cancer and bladder cancer-associated macrophages

  2023cites this paper
• CRTC2 promotes paclitaxel resistance by inducing autophagy in ovarian cancer in part via the PI3K-AKT signaling axis

  2023cites this paper
• Emerging Roles for Mammalian Target of Rapamycin (mTOR) Complexes in Bladder Cancer Progression and Therapy

  2022cites this paper
• Expression of Rab1A in bladder cancer and its clinical implications

  2020cites this paper
• mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy

  2019influential citation
• Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models

  2019cites this paper
• DHCR24 predicts poor clinicopathological features of patients with bladder cancer

  2018cites this paper
• An orthotopic xenograft model for high-risk non-muscle invasive bladder cancer in mice: influence of mouse strain, tumor cell count, dwell time and bladder pretreatment

  2017cites this paper
• Therapeutic implication of mTORC2 in oral squamous cell carcinoma.

  2017cites this paper
• A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies

  2016cites this paper
• mTOR inhibitors in urinary bladder cancer

  2016influential citation
• Rational Combinations of mTOR Inhibitors as Anticancer Strategies

  2016cites this paper
• PP242 suppresses bladder cancer cell proliferation and migration through deactivating the mammalian target of rapamycin complex 2/AKT1 signaling pathway.

  2016cites this paper
• Everolimus enhances cellular cytotoxicity of lapatinib via the eukaryotic elongation factor-2 kinase pathway in nasopharyngeal carcinoma cells

  2016cites this paper
• The route to personalized medicine in bladder cancer: where do we stand?

  2015cites this paper
• Emerging therapeutic targets in bladder cancer.

  2015cites this paper
• Hyperphosphorylation of ribosomal protein S6 predicts unfavorable clinical survival in non-small cell lung cancer

  2015cites this paper
• Bladder cancer: molecular determinants of personalized therapy.

  2015cites this paper
• OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo

  2015cites this paper
• Pirarubicin induces an autophagic cytoprotective response through suppression of the mammalian target of rapamycin signaling pathway in human bladder cancer cells.

  2015cites this paper
• Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells

  2015cites this paper
• Targeting the genetic alterations of the PI3K-AKT-mTOR pathway: its potential use in the treatment of bladder cancers.

  2015cites this paper
• Cancers of the Urinary System

  2014cites this paper
• Time now to TORC the TORC? New developments in mTOR pathway inhibition in lymphoid malignancies

  2014cites this paper
• Lapatinib induces autophagic cell death and inhibits growth of human hepatocellular carcinoma

  2014cites this paper